# Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

> **NCT06538896** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Triple-negative Breast Cancer
- Bone Metastases

## Interventions

- **DRUG:** Tislelizumab + Nab-Paclitaxel
- **OTHER:** Rankl inhibitor

## Key facts

- **NCT ID:** NCT06538896
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-20
- **Primary completion:** 2026-12
- **Final completion:** 2027-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538896, "Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06538896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*